NCT00661336View on ClinicalTrials.gov

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2009

Conditions
Melanoma (Skin)
Interventions
DRUG

buthionine sulfoximine

DRUG

melphalan

GENETIC

microarray analysis

OTHER

high performance liquid chromatography

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

biopsy

Trial Locations (2)

27710

Duke Comprehensive Cancer Center, Durham

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00661336 - A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma | Biotech Hunter | Biotech Hunter